Neha Vapiwala | OMICS International
ISSN: 2165-7386

Journal of Palliative Care & Medicine
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Neha Vapiwala

Center for Clinical Epidemiology and Biostatistics University of Pennsylvania Department of Radiation Oncology Perelman School of Medicine ,USA


Neha Vapiwala is affiliated to Center for Clinical Epidemiology and Biostatistics ,University of Pennsylvania.She specialize in the management of patients with genitourinary (GU) cancers, and served as the department’s GU Service Chief, working collaboratively with members of the Departments of Urology, Medical Oncology, Pathology, Diagnostic Radiology and Nuclear Medicine to further our mission of providing high-quality multidisciplinary patient care and performing cutting-edge clinical research. Her work focuses on biological and technological improvements in the delivery of photon- and proton-based radiation, and I currently serve as the Principal Investigator of multiple therapeutic trials for prostate cancer patients. She have been a Project Leader on a Department of Defense program project grant investigating proton therapy, and have extramural funding to develop prognostic and predictive biomarkers for novel radio sensitizers in conjunction with radiotherapy, as well as to explore the effect of yoga as a therapeutic intervention on disease- and treatment-related symptoms in prostate cancer patients undergoing external beam radiation.

Research Interest

breast cancer, prostate cancer, image-guided radiation therapy, biologic agents, radiosensitizers.